Matt Kaeberlein: Finally! A large clinical trial of rapamycin for healthy aging

Key Takeaways

• Watch for results from the upcoming 720-person clinical trial testing rapamycin (likely 8mg/week dose) on frailty prevention and IL-6 reduction in adults 65+.
• Monitor safety markers if taking rapamycin: trough levels should stay below 5 ng/mL to avoid immunosuppression.
• Prioritize functional health metrics like joint mobility, lung function (spirometry), and skin biomarkers (glycation products) when assessing aging interventions.
• Consider weekly dosing – preliminary data shows no accumulation with once-weekly rapamycin (4-8mg).

Supplements & Protocols Mentioned

• Rapamycin test doses: 4mg/week and 8mg/week (once-weekly dosing)

Notable Quotes

“We wanted to make sure that [rapamycin trough levels] stayed below five nanograms per milliliter… nobody had serious adverse events.”

Bottom Line

Track upcoming results from this large rapamycin trial (expected 2024-2025) before considering off-label use, and prioritize functional health markers over theoretical biomarkers when evaluating anti-aging interventions.

Watch the Full Video